The tweet was deleted by the author.
But we saved everything 🙂.
NovoCure Ltd announced positive outcomes today from the Phase 2 PANOVA-4 trial evaluating its Tumor Treating Fields (TTFields) therapy.
The company released the results in a press statement, marking a significant milestone for its ongoing research efforts. TTFields therapy is an innovative, non-invasive treatment modality targeting tumor growth. Further details on the trial findings and next steps are available in NovoCure Ltd's official press release.
NovoCure Ltd recently received Japanese government approval for insurance reimbursement of its lung cancer treatment, according to a prior announcement here. The company also delivered its financial results for the quarter and full year ended December 31, 2025 here. These updates provide additional context for NovoCure’s ongoing clinical and commercial initiatives.